Zhang Wentao, Zhang Junfeng, Zhang Ziwei, Guo Yadong, Wu Yuan, Wang Ruiliang, Wang Longsheng, Mao Shiyu, Yao Xudong
Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China; Anhui Medical University, Hefei 230032, PR China.
Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China.
Transl Oncol. 2019 Mar;12(3):485-492. doi: 10.1016/j.tranon.2018.11.012. Epub 2018 Dec 26.
Indoleamine 2,3-dioxygenase 1 (IDO1) is a key enzyme in tryptophan metabolism and plays an important role in tumor cell immunosuppression and angiogenesis. The molecular mechanisms of IDO1 and epithelial-mesenchymal transition (EMT) have not been elucidated or studied in bladder cancer. Therefore, the aims of this study were to detect IDO1 expression in bladder cancer tissues and then to investigate the role of IDO1 in bladder cancer cell EMT and malignant phenotypes as well as the underlying molecular mechanisms. By immunohistochemistry, Western blot, and quantitative reverse transcription-polymerase chain reaction experiments, IDO1 was found to be overexpressed in bladder cancer tissues and cell lines compared to the noncancerous ones. In addition, knockdown of IDO1 expression was shown to inhibit bladder cancer cell growth, migration, invasion, and EMT. Furthermore, we demonstrated that IDO1 may promote EMT by activation of the interleukin 6/signal transducer and activator of transcription 3/programmed cell death ligand 1 signaling pathway. Collectively, these data suggest that IDO1 may play an important role in bladder cancer and may be a novel therapeutic target for patients with bladder cancer.
吲哚胺2,3-双加氧酶1(IDO1)是色氨酸代谢中的关键酶,在肿瘤细胞免疫抑制和血管生成中起重要作用。IDO1与上皮-间质转化(EMT)的分子机制在膀胱癌中尚未阐明或研究。因此,本研究的目的是检测IDO1在膀胱癌组织中的表达,然后研究IDO1在膀胱癌细胞EMT和恶性表型中的作用以及潜在的分子机制。通过免疫组织化学、蛋白质印迹和定量逆转录-聚合酶链反应实验,发现与非癌组织相比,IDO1在膀胱癌组织和细胞系中过表达。此外,IDO1表达的敲低显示可抑制膀胱癌细胞的生长、迁移、侵袭和EMT。此外,我们证明IDO1可能通过激活白细胞介素6/信号转导和转录激活因子3/程序性细胞死亡配体1信号通路促进EMT。总体而言,这些数据表明IDO1可能在膀胱癌中起重要作用,可能是膀胱癌患者的一个新的治疗靶点。